Literature DB >> 28724267

Association of Neo Angiogenesis by CD34 Expression and Clinicopathologic Features in Squamous Cell Carcinoma of Cervix.

Soheila Sarmadi1, Narges Izadi-Mood1, Fatemeh Movarei1, Salma Sefidbakht2, Kambiz Sotoudeh3, Eesa Jahanzad4.   

Abstract

Tumor angiogenesis is one of the most important factors in tumor progression. In this study, the angiogenesis of cervical squamous cell carcinoma (SCC) and its association with prognostic factors was assessed by using CD34 immunostaining marker. The microvessel density in 40 patients with cervical SCC was studied in three areas of the tumor; stromal and peripheral tumor area (combined) central stromal tumor area and peripheral tumor area and the relationship of microvascular density and survival was also evaluated. The count of CD34 is correlated with younger age, the presence of perineural invasion and metastasis to lymph nodes. High peripheral tumor angiogenesis is also correlated with lower disease-free tumor survival. According to the findings of the present study, CD34 expression, especially in peripheral tumor areas, can be used as a prognostic marker in cervical SCC.

Entities:  

Keywords:  Angiogenesis; CD34; Cervical squamous cell carcinoma; Prognostic marker

Mesh:

Substances:

Year:  2017        PMID: 28724267

Source DB:  PubMed          Journal:  Acta Med Iran        ISSN: 0044-6025


  2 in total

1.  Dl-3-n-Butylphthalide promotes neovascularization and neurological recovery in a rat model of intracerebral hemorrhage.

Authors:  Ewen Tu; Qiong Chen; Li Tan; Yan Wang
Journal:  BMC Neurosci       Date:  2020-05-29       Impact factor: 3.288

2.  Vascular endothelial growth factor (VEGF) polymorphism rs3025039 and atherosclerosis among older with hypertension.

Authors:  Yuji Shimizu; Kazuhiko Arima; Yuko Noguchi; Hirotomo Yamanashi; Shin-Ya Kawashiri; Kenichi Nobusue; Fumiaki Nonaka; Kiyoshi Aoyagi; Yasuhiro Nagata; Takahiro Maeda
Journal:  Sci Rep       Date:  2022-04-01       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.